TransMedics Group (NASDAQ:TMDX) Given Outperform Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $125.00 price objective on the stock.

Several other analysts have also recently issued reports on TMDX. Robert W. Baird cut their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Piper Sandler reduced their price target on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Tuesday. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $71.44 on Tuesday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company’s fifty day moving average price is $108.52 and its two-hundred day moving average price is $135.34. The firm has a market capitalization of $2.40 billion, a P/E ratio of 76.00 and a beta of 2.06. TransMedics Group has a 12 month low of $68.84 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the company posted ($0.12) EPS. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. On average, research analysts anticipate that TransMedics Group will post 1.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,958 shares of company stock valued at $3,470,328 in the last three months. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of TransMedics Group

A number of institutional investors have recently made changes to their positions in TMDX. State of Alaska Department of Revenue bought a new stake in TransMedics Group during the third quarter worth approximately $2,560,000. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after buying an additional 64,360 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after buying an additional 6,634 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after buying an additional 64,872 shares in the last quarter. Finally, Thrivent Financial for Lutherans acquired a new position in TransMedics Group during the third quarter worth about $4,113,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.